Comments on: 91�� Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA

Comments on: 91�� Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA /bluerock-therapeutics-investigational-cell-therapy-lemiretprocel-opct-001-for-primary-photoreceptor-diseases-granted-orphan-drug-designations-by-fda-and-ema/ Wed, 30 Sep 2026 06:52:44 +0000 hourly 1 https://wordpress.org/?v=7.1.2